(Q42731308)

6 November 2017

Rebound effect following intravitreal bevacizumab in branch retinal vein occlusion (English)

1 reference

6 November 2017

1 reference

Satyen Deka

1

1 reference

6 November 2017

Kruto Kalita

series ordinal

2

1 reference

6 November 2017

Sunil Kumar Singh

series ordinal

3

1 reference

6 November 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Oman Journal of Ophthalmology

6 November 2017

1 reference

6 November 2017

2

1 reference

6 November 2017

2

1 reference

6 November 2017

94-95

1 reference

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion

6 November 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905188

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

27 May 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905188

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

27 May 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2905188

16 August 2018

Retinal vein occlusion

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20671839

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20671839

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4103/0974-620X.53042

1 reference

6 November 2017

1 reference

6 November 2017

PubMed publication ID

20671839

1 reference